The TRUST (TReatment with Unique recombinant rFVIIa STudy) trial is a Phase II/III, multicenter, open-label clinical study designed to assess the safety and efficacy of BAY 86-6150, a recombinant factor VIIa (rFVIIa) protein, in patients with hemophilia A
or B with inhibitors.
The prospective, open label, randomized, multi-center, parallel study investigated the efficacy, safety and health-related quality of life benefits of FEIBA NF prophylactic treatment compared to on-demand treatment in 36 patients with hemophilia A
or B and inhibitors over a 12-month period.
In 2014, the 9MM had 60,671 diagnosed prevalent cases of hemophilia A
and hemophilia B, around 28% of which occurred in the US.
In the recent study, scientists removed a piece of skin from the arms of six people with severe hemophilia A
, also called as classical hemophilia or factor VIII deficiency hemophilia, is caused by deficiency of clotting factor VIII.
Patients with hemophilia A
or hemophilia B are dependent on protein replacement therapy with Factor VIII or Factor IX, respectively, for life.
Eventually, the team hopes to extend their work to hemophilia A
, the more common form of the disease.
Baxter will acquire worldwide rights to OBI-1, a recombinant porcine factor VIII in development for congenital hemophilia A
with inhibitors and acquired hemophilia A
Forty caregivers were recruited, a majority of whom had a child with hemophilia A
But it has long posed a paradox: Some boys with hemophilia A
are endangered by any bump or scrape, while others have such mild forms that the disorder goes undetected until they lose their first tooth.
OBI-1 is a recombinant porcine factor VIII (rpFVIII) being investigated for the treatment of bleeding in people with acquired hemophilia A
and congenital hemophilia A
patients with inhibitors.
For instance, the American Thrombosis & Hemostasis Network, Bloodworks Northwest (formerly Puget Sound Blood Center), the National Hemophilia Foundation and Biogen founded My Life, Our Future, a program that offers free genetic testing to individuals with hemophilia A
and B in the United States.